XFOR Overview

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Wall Street analysts forecast XFOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XFOR is57.75 USD with a low forecast of 7.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

X4 Pharmaceuticals Inc revenue for the last quarter amounts to 28.81M USD, decreased

X4 Pharmaceuticals Inc. EPS for the last quarter amounts to 1.20 USD, decreased -115.44

X4 Pharmaceuticals Inc (XFOR) has 143 emplpoyees as of July 08 2026.

Today XFOR has the market capitalization of 112.53M USD.